Welcome to the e-CCO Library!

P640: Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel Diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Edelman-Klapper, H.(1,2)*;Rabinowitz, K.M.(1,3); Zittan, E.(4,5);Bar-Gil Shitrit, A.(6,7);Goren, I.(1,2);Avni-Biron, I.(1,2);Ollech, J.E.(1,2);Lichtenstein, L.(8);Banai-Eran, H.(1,2);Yanai, H.(1,2);Snir, Y.(1,2);Pauker, M.H.(1,2);Friedenberg, A.(1);Levy-Barda, A.(9);Segal, A.(10);Broitman, Y.(1,2);Maoz, E.(11);Ovadia, B.(12);Aharoni Golan, M.(1,2);Shachar, E.(2,13);Ben-Horin, S.(2,13);Mor, M.(11);Ben Zvi, H.(2,14);Perets, T.T.(15,16);Eliakim, R.(2,13);Barkan, R.(1);Navon, M.(17);Gal-Tanamy, M.(18);Freund, N.T.(17);Goren, S.(19);Cohen, D.(19);Dotan, I.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P640: Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome – a prospective study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rowan C.R.*1, Kalei A.2, De Vries A.2, Cullen G.3,4, Ryan E.1,4, Mulcahy H.3,4, D'Haens G.5, Doherty G.A.3,4

Created: Wednesday, 20 February 2019, 10:36 AM
P641 An increased baseline mucosal TNF burden linked to adalimumab non-response: opportunities for therapeutic drug monitoring
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Verstockt1, J. Stylli2, P. Rahimian2, A. Rajulapati2, K. Ehring2, D. Thomas3, J. Sabino1, M. Ferrante1, S. Singh2, S. Vermeire1

Created: Thursday, 30 January 2020, 10:12 AM
P641: Bowel Doppler Signal, the most important ultrasonographic feature in clinical practice in managing Inflammatory Bowel Diseases patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Les, A.(1)*;Cotruta, B.(1);Iacob , R.(1,2);Saizu, R.(1,2);Gheorghe, L.(1,2);Gheorghe, C.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P641: Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: A prospective randomised clinical trial (CORRECT study)
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Kato1*, K. Kani1, H. Kurihara2, T. Ohmori3, K. Yakabi1

Created: Thursday, 21 February 2019, 9:14 AM
P641: Impact of lockdown period due to COVID-19 pandemic in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: García Mateo, S.(1,2);Refaie, E.(3);Martínez-Domínguez, S.J.(1,2);Gargallo-Puyuelo, C.J.(1,2,4);Lario Quilez, L.(1);Carrera-Lasfuentes, P.(5);Arroyo Villarino, M.T.(1,2,4);Aso Gonzalvo, M.C.(1);Gomollón García, F.(1,2,4,5);
Created: Wednesday, 2 June 2021, 4:12 PM
P641: Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey
Year: 2022
Source: ECCO'22
Authors: Revés, J.(1);Abreu, B.(1);Chaparro, M.(2);Gisbert, J.P.(2);Mariangela, A.(3);Fiorino, G.(3);Barberio, B.(4);Zingone, F.(4);Pisani, A.(5);Cassar, D.(5);Michalopoulos, G.(6);Mantzaris, G.(7);Mountaki, K.(7);Koutroubakis, I.(8);Karmiris, K.(9);Katsanos, K.(10);Ďuricova, D.(11);Burisch, J.(12);Madsen, G.R.(12);Maaser, C.(13);Naila, A.(14);Orfanoudaki, E.(8);Milivojevic, V.(15);Buisson, A.(16);Avedano, L.(17);Leone, S.(18);Torres, J.(1);Ellul, P.(5);
Created: Friday, 11 February 2022, 3:56 PM
P641: Long-term outcome of adalimumab therapy and predictors of response in 254 patients with Crohn's disease: a hospital-based cohort study from Korea
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Seo H.*1, Ye B.D.1,2, Lee S.-H.1, Chang K.1, Song E.M.1, Kim G.-U.1, Seo M.1, Lee H.-S.3, Hwang S.W.1,2, Park S.H.1,2, Yang D.-H.1, Kim K.-J.1,2, Byeon J.-S.1, Myung S.-J.1, Yang S.-K.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P641: Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Kolar*1, K. Pudilova1, M. Bortlik1,2,3, D. Duricova1, K. Malickova1,4, M. Lukas1, V. Hruba1, N. Machkova1, R. Vanickova1, K. Mitrova1, M. Vasatko1, M. Lukas1,4

Created: Friday, 22 February 2019, 9:41 AM
P642 Serum adalimumab levels measured between days 9 and 13 from drug injection can be interpreted clinically in a similar way to trough levels in patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Guardiola Capón1, K. Serra1, L. Rodríguez-Alonso1, E. Santacana2, N. Padullés2, A. Ruiz-Cerulla1, C. Arajol1, B. Camps1, G. Surís1, E. Sanchez1, F. Rodríguez-Moranta1

Created: Thursday, 30 January 2020, 10:12 AM
P642: Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Dreesen1*, R. Faelens1, G. Van Assche2,3, M. Ferrante2,3, S. Vermeire2,3, A. Gils1, T. Bouillon1

Created: Thursday, 21 February 2019, 9:14 AM
P642: Anxiety and depression: beyond simple consequences of chronic inflammatory bowel diseases
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. Timofte*1, E. Gologan1, A. S. Leca2, G-E. Galca-Blanariu1,2, G. Stefanescu1,2

Created: Friday, 22 February 2019, 9:41 AM
P642: Crossroads of vitamin B6 deficiency and inflammation in inflammatory bowel disease: Preliminary results of a cross-sectional study
Year: 2022
Source: ECCO'22
Authors: Farrag, K.(1,2);Woldeab, J.(3);Stein, J.M.(1,2,4);Aksan, A.(2,5);
Created: Friday, 11 February 2022, 3:56 PM
P642: Effects of Covid-19 on employment in IBD patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Sciberras, M.(1);Nascimento, C.(2);Tabone, T.(1);Karmiris, K.(3);Nikolaou, P.(3);Theodoropoulou, A.(3);Mula, A.(1);Goren, I.(4);Yanai, H.(4);Amir, H.(4);Mantzaris, G.(5);Georgiadi, T.(5);Foteinogiannopoulou, K.(6);Koutroubakis, I.(6);Allocca, M.(7);Fiorino, G.(7);Furfaro, F.(7);Katsanos, K.H.(8);Fousekis, F.(8);Michalopoulos, G.(9);Torres, J.(2);Ellul, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P642: Impact of histological and endoscopic remission in clinical recurrence and recurrence-free time in ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ponte A., Pinho R., Fernandes S., Rodrigues A., Alberto L., Silva J., Rodrigues J., Sousa M., Leite S., Silva A.P., Proença L., Freitas T., Carvalho J.

Created: Wednesday, 20 February 2019, 10:36 AM
P642: Network meta-analysis: efficacy and safety of treatments for fistulising Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chahal, J.(1);Sriranganathan, D.(2);Poo, S.(3);Lo, S.W.(4)*;Kashkooli, S.(4);Garg, M.(4,5);Segal, J.P.(4,5);
Created: Friday, 14 July 2023, 11:12 AM
P643 Development of quantitative ultrasonographic activity score in ileal Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Livne Margolin1, M. Amitai2, E. Klung2, B. Ungar1, R. Eliakim1, S. Ben-Horin1, D. Carter1, U. Kopylov1

Created: Thursday, 30 January 2020, 10:12 AM
P643: Effectiveness of enhanced recovery after surgery in IBD: a propensity score matched cohort study in a single Italian centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Mineccia1, M. Daperno*2, P. Massucco1, F. Menonna1, V. Gentile1, P. Germani1, M. Mendolaro2, R. Rocca2, A. Ferrero1

Created: Friday, 22 February 2019, 9:41 AM
P643: Filgotinib decreases systemic and mucosal markers of inflammation that are associated with endoscopic improvement in moderately to severely active Crohn’s disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

X. Roblin1*, G. D'Haens2, R. Galien3, L. Goyal4, W. Li4, A. Mirza4, A. Serone4, C. Tasset5, A. Van der Aa5, J. Woo4, S. Vermeire6

Created: Thursday, 21 February 2019, 9:14 AM
P643: Generalizability of Crohn’s disease randomized controlled trials compared to clinical practice
Year: 2022
Source: ECCO'22
Authors: Chhibba, T.(1);Frolkis, A.(2);Ma, C.(2);
Created: Friday, 11 February 2022, 3:56 PM